{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"1882","value":"402.0"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"2030","value":"522.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"Time on treatment was defined as the time from the first to the last dose of study drug. For participants who have not discontinued, time on treatment was censored as of the last dose of the study drug.","dispersionType":"Full Range","groups":[{"description":"Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).","id":"OG000","title":"Brigatinib 90 mg"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).","id":"OG001","title":"Brigatinib 90 mg - 180 mg"}],"paramType":"MEDIAN","populationDescription":"Safety Population included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to approximately 69 months","title":"Time on Treatment","type":"SECONDARY","unitOfMeasure":"days"}